Dosimetry, efficacy, and safety of three-dimensional printing noncoplanar template-assisted and CT-guided 125I seed implantation for recurrent retroperitoneal lymphatic metastasis after external beam radiotherapy
Dosimetry, efficacy, and safety of three-dimensional printing noncoplanar template-assisted and CT-guided 125I seed implantation for recurrent retroperitoneal lymphatic metastasis after external beam radiotherapy
复制标题
DOI：
10.1016/j.brachy.2020.02.009
复制
发表时间：
2020-05-01
期刊：
影响因子：
1.9
通讯作者：
Wang, Junjie
中科院分区：
文献类型：
--
作者：
Chen, Yi;Jiang, Yuliang;Wang, Junjie
目的：评价三维打印非共面模板（3D-PNCT）和CT辅助放射性I-125种子植入（RISI）治疗既往外照射放疗后复发性腹膜后淋巴转移（RRLM）的剂量学、有效性和安全性。方法和材料：2016年6月至2018年8月，32例RRLM患者成功接受了3D-PNCT辅助和CT引导的RISI。对剂量学、疼痛缓解率、行为改善率、总缓解率、疾病控制率、局部控制时间（LCT）、总生存期（OS）和安全性进行评价。剂量学结果显示，手术前后D90、D100、V100、V150、V200和均匀性指数基本一致（p > 0.05），外折射率和适形折射率除外（p = 0.048，p = 0.034）。RISI后，81.3%的患者疼痛缓解，71.9%的患者表现改善。总有效率和疾病控制率分别为85.3%和94.1%。1年和2年的LCT率分别达到66.2%和43.2%，中位LCT为15.8个月。1年和2年的OS率分别为74.1%和28.1%，中位OS为17.6个月。单因素分析显示，当D90 > 130戈伊或D100 > 63戈伊或肿瘤大小
OBJECTIVES: To evaluate the dosimetry, efficacy, and safety of radioactive I-125 seed implantation (RISI) assisted by three-dimensional printing noncoplanar template (3D-PNCT) and CT for recurrent retroperitoneal lymphatic metastasis (RRLM) after previous external beam radiotherapy.METHODS AND MATERIALS: From June 2016 to August 2018, 32 patients with RRLM successfully underwent 3D-PNCT-assisted and CT-guided RISI. The dosimetry, pain relief rate, performance improvement rate, overall response rate, disease control rate, local control time (LCT), overall survival (OS), and safety profiles were evaluated.RESULTS: Dosimetric results showed that the D90, D100, V100, V150, V200, and homogeneity index were consistent in preoperation and postoperation (p > 0.05), except for the external index and conformal index (p = 0.048, p = 0.034). After RISI, 81.3% of the patients achieved pain relief, and 71.9% achieved an improvement of performance. The overall response rate and disease control rate were 85.3% and 94.1%, respectively. The LCT rates reached 66.2% and 43.2% in 1 year and two years, respectively, with a median LCT of 15.8 months. The OS rates were 74.1% and 28.1% in 1 year and two year, respectively, with a median OS reaching 17.6 months. Univariate analysis showed that when D90 > 130 Gy or D100 > 63 Gy or tumor size